Everolimus Versus Placebo in Head and Neck Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

April 30, 2018

Study Completion Date

October 31, 2018

Conditions
Head and Neck Cancer
Interventions
DRUG

Everolimus (RAD 001)

10mg of Everolimus or Placebo taken by mouth once daily for 1 year or until progression (whichever comes first).

OTHER

Placebo

Trial Locations (17)

27599

University of North Carolina, Chapel Hill

29425

Medical University of South Carolina Hollings Cancer Center, Charleston

33136

University of Miami, Miami

37232

Vanderbilt University, Nashville

39216

University of Mississippi, Jackson

43210

Ohio State University, Columbus

48109

University of Michigan, Ann Arbor

55455

University of Minnesota, Minneapolis

60426

Ingalls Cancer Research Center, Harvey

60611

Northwestern University, Chicago

60612

University of Illinois-Chicago, Chicago

60637

The University of Chicago Medical Center, Chicago

63110

Washington University, St Louis

66160

University of Kansas, Kansas City

71130

Louisianna State University, Shreveport

77555

The University of Texas Medical Branch at Galveston, Galveston

02111

Tufts Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Chicago

OTHER